McKesson

At the Morgan Stanley Healthcare Conference, McKesson raised its EPS outlook for 2027 to $44.20–45.00 and sees reported growth of 13–15%. Strong results in the Oncology and Multispecialty segment and expansion in oncology and biopharma services—including the planned acquisition of Precision Medicine Group—are driving the improvement. The med-surg business is under pressure, while buybacks, higher dividends and a planned spinoff of Wellverse support capital allocation and shareholder returns. » Więcej na de.investing.com

McKesson plans to acquire Precision Medicine Group for $2.25 billion to add oncology-focused CRO, clinical-trial and market-access capabilities to its Oncology and Multi-Specialty segment, subject to regulatory approval. The company reported strong first-quarter results, with North American Pharmaceutical Distribution revenue up ~5% and Oncology and Multi-Specialty revenue and profit rising about 33% and 41%, respectively. McKesson expects to return roughly $5 billion to shareholders this year, including $2.5 billion in buybacks and a 15% dividend increase, while continuing investments in automation, AI and other growth initiatives. The firm is also progressing with the separation of its Medical-Surgical business, rebranded as Wellverse, targeted for the back half of next year. » Więcej na finance.yahoo.com

McKesson will acquire Precision Medicine Group for about $2.25 billion to expand its Oncology & Multispecialty business with clinical research, lab testing and commercialization services. The deal aligns with McKesson's strategy of exiting non-core assets and investing in higher-growth specialty and oncology areas. Management expects the acquisition to strengthen clinical trial execution and biopharma offerings, but no closing timeline was provided and integration, scalability and near-term earnings impact remain uncertain. » Więcej na finance.yahoo.com